Additional studies are needed to clarify the exact mechanisms and possibilities, as HER2 is an attractive therapeutic target for gastric, colorectal, and ovarian cancer, and the STAT3 signaling pathway is connected with HER2 overexpression in ovarian cancer [131]. This evidence concerns the gene STAT3 and ovarian carcinoma.